Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway
Journal of Cellular and Molecular Medicine · 2023-02 · 27 (3) · 403-411
DOI: 10.1111/jcmm.17663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.01.2023. Verfasst von Xiaoyu Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, Weifang Medical University, Weifang, China. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Prostate cancer (PCa) is one of the most common malignancies in men. Ribosomal protein L22‐like1 (RPL22L1), a component of the ribosomal 60 S subunit, is associated with cancer progression, but the role and potential mechanism of RPL22L1 in PCa remain unclear. The aim of this study was to investigate the role of RPL22L1 in PCa progression and the mechanisms involved. Bioinformatics and immunohistochemistry analysis showed that the expression of RPL22L1 was significantly higher in PCa tissues than in normal prostate tissues. The cell function analysis revealed that RPL22L1 significantly promoted the proliferation, migration and invasion of PCa cells. The data of xenograft tumour assay suggested that the low expression of RPL22L1 inhibited the growth and invasion of PCa cells in vivo. Mechanistically, the results of Western blot proved that RPL22L1 activated PI3K/Akt/mTOR pathway in PCa cells. Additionally, LY294002, an inhibitor of PI3K/Akt pathway, was used to block this pathway. The results showed that LY294002 remarkably abrogated the oncogenic effect of RPL22L1 on PCa cell proliferation and invasion. Taken together, our study demonstrated that RPL22L1 is a key gene in PCa progression and promotes PCa cell proliferation and invasion via PI3K/Akt/mTOR pathway, thus potentially providing a new target for PCa therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Science and Technology, Weifang Medical University, Weifang, China.
- Department of Urology Surgery, Shandong Cancer Hospital and Institute, Jinan, China.
- Department of Urology Surgery, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Urology Surgery, Affiliated Hospital of Weifang Medical University, Weifang, China.
ORCID-Profile: Weiguo Feng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Yi, X., Zhang, C., Liu, B., Gao, G., Tang, Y., Lu, Y., Pan, Z., Wang, G., & Feng, W. (2023). Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway. Journal of Cellular and Molecular Medicine, 27(3), 403-411. https://doi.org/10.1111/jcmm.17663
Vancouver
Yi X, Zhang C, Liu B, Gao G, Tang Y, Lu Y, et al. Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway. Journal of Cellular and Molecular Medicine. 2023;27(3):403-411. doi:10.1111/jcmm.17663
BibTeX
@article{Yi2023,
author = {Yi, Xiaoyu and Zhang, Chao and Liu, Baojie and Gao, Guojun and Tang, Yaqi and Lu, Yongzheng and Pan, Zhifang and Wang, Guohui and Feng, Weiguo},
title = {Ribosomal protein L22‐like1 promotes prostate cancer progression by activating PI3K/Akt/mTOR signalling pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2023},
volume = {27},
number = {3},
pages = {403--411},
doi = {10.1111/jcmm.17663}
}
EUVIMED